1. Home
  2. NOAH vs DNTH Comparison

NOAH vs DNTH Comparison

Compare NOAH & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOAH
  • DNTH
  • Stock Information
  • Founded
  • NOAH 2005
  • DNTH 2015
  • Country
  • NOAH China
  • DNTH United States
  • Employees
  • NOAH N/A
  • DNTH N/A
  • Industry
  • NOAH Investment Managers
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOAH Finance
  • DNTH Health Care
  • Exchange
  • NOAH Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • NOAH 618.3M
  • DNTH 657.0M
  • IPO Year
  • NOAH 2010
  • DNTH N/A
  • Fundamental
  • Price
  • NOAH $9.50
  • DNTH $19.59
  • Analyst Decision
  • NOAH Hold
  • DNTH Strong Buy
  • Analyst Count
  • NOAH 3
  • DNTH 8
  • Target Price
  • NOAH $12.50
  • DNTH $54.33
  • AVG Volume (30 Days)
  • NOAH 111.3K
  • DNTH 251.8K
  • Earning Date
  • NOAH 05-28-2025
  • DNTH 05-16-2025
  • Dividend Yield
  • NOAH 22.30%
  • DNTH N/A
  • EPS Growth
  • NOAH N/A
  • DNTH N/A
  • EPS
  • NOAH 0.92
  • DNTH N/A
  • Revenue
  • NOAH $356,342,836.00
  • DNTH $6,235,000.00
  • Revenue This Year
  • NOAH N/A
  • DNTH N/A
  • Revenue Next Year
  • NOAH $6.37
  • DNTH N/A
  • P/E Ratio
  • NOAH $10.21
  • DNTH N/A
  • Revenue Growth
  • NOAH N/A
  • DNTH 120.63
  • 52 Week Low
  • NOAH $7.14
  • DNTH $13.37
  • 52 Week High
  • NOAH $15.44
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • NOAH 51.97
  • DNTH 45.90
  • Support Level
  • NOAH $9.38
  • DNTH $20.76
  • Resistance Level
  • NOAH $9.60
  • DNTH $22.14
  • Average True Range (ATR)
  • NOAH 0.27
  • DNTH 1.50
  • MACD
  • NOAH 0.11
  • DNTH -0.13
  • Stochastic Oscillator
  • NOAH 75.51
  • DNTH 5.53

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: